Skip to main content

News and blog posts

10
Aug 2018

Oleg Borisenko co-authored health economic analysis of Barostim for heart failure

An article “An early analysis of cost-utility of baroreflex activation therapy in advanced chronic heart failure in Germany” was published in the BMC Cardiovascular Disorders. The study concluded that Baroreflex activation therapy (BAT) using the Barostim neo™ device (CVRx Inc., Minneapolis, MN, USA) compared with optimized medical management in patients with advanced chronic heart failure (NYHA class III) who were not eligible for treatment with cardiac resynchronization therapy, can be cost-effective from a statutory health insurance perspective in Germany over a lifetime horizon. The ICER was €27,951/QALY (95% CI €21,357–82,970).
31
Jul 2018

Russian Ministry of Health plans to re-equip vascular surgery centers

Minister of Health announced that it is planned to re-equip 609 vascular surgery centers. In parallel, about 30 departments will be upgraded to the level of the regional vascular centers, which will increase their capacity. Ministry plans that these efforts will help to double number of primary coronary interventions in acute coronary syndrome in Russia.